Ovarian microbiota and Ovarian cancer: an overview and update meta-analysis
Keywords:
Ovarian Cancer , Ovarian Microbiota, DysbiosisAbstract
Background: Ovarian cancer (OC) remains the most lethal gynecological malignancy, although advancements in treatment strategies. Emerging data suggested the potential role of ovarian microbiota in ovarian cancer pathogenesis. The objective of this review and meta-analysis is to analyze available literature to investigate this correlation.
Methods: According to the recommendations in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement, the Pubmed database and the Embase database were searched in February 2024. No limitation of the countries was considered.
Results: Twenty-seven studies met the inclusion criteria. Five thousand and fourteen ovarian carcinoma cases were included of which 1659 (33.1%) showed dysbiosis. The fixed-effect model and the random-effect model showed no significant correlation between ovarian cancer patients and dysbiosis (p<0.001 and p<0.001 with 95% Confidence Interval 0.21-0.35 and effect size 0.28, respectively). The heterogeneity between studies was high with an I2 of 95.76% (p<0.001).
Conclusions: Our meta-analysis suggests no significant difference in dysbiosis prevalence between OC patients and controls. Considering the substantial heterogeneity found, more studies with control groups and precise methodologies are needed to further evaluate the potential role of the ovarian microbiota in the OC.
References
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5-29. doi:10.3322/caac.21254
Torre LA, Islami F, Siegel RL, Ward EM, Jemal A. Global Cancer in Women: Burden and Trends. Cancer Epidemiology, Biomarkers & Prevention. 2017;26(4):444-457. doi:10.1158/1055-9965.EPI-16-0858
Di Donna MC, Cucinella G, Zaccaria G, et al. Concordance of Radiological, Laparoscopic and Laparotomic Scoring to Predict Complete Cytoreduction in Women with Advanced Ovarian Cancer. Cancers (Basel). 2023;15(2):500. doi:10.3390/cancers15020500
Janavičius R. Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control. EPMA Journal. 2010;1(3):397-412. doi:10.1007/s13167-010-0037-y
Carlson JW, Miron A, Jarboe EA, et al. Serous Tubal Intraepithelial Carcinoma: Its Potential Role in Primary Peritoneal Serous Carcinoma and Serous Cancer Prevention. Journal of Clinical Oncology. 2008;26(25):4160-4165. doi:10.1200/JCO.2008.16.4814
Chambers LM, Bussies P, Vargas R, et al. The Microbiome and Gynecologic Cancer: Current Evidence and Future Opportunities. Curr Oncol Rep. 2021;23(8):92. doi:10.1007/s11912-021-01079-x
Cazzaniga M, Cardinali M, Di Pierro F, Bertuccioli A. Ovarian Microbiota, Ovarian Cancer and the Underestimated Role of HPV. Int J Mol Sci. 2022;23(24). doi:10.3390/ijms232416019
PRICE MJ, ADES AE, WELTON NJ, SIMMS I, HORNER PJ. Pelvic inflammatory disease and salpingitis: incidence of primary and repeat episodes in England. Epidemiol Infect. 2017;145(1):208-215. doi:10.1017/S0950268816002065
Zhou Z, Zeng F, Yuan J, et al. Pelvic inflammatory disease and the risk of ovarian cancer: a meta-analysis. Cancer Causes & Control. 2017;28(5):415-428. doi:10.1007/s10552-017-0873-3
Fortner RT, Terry KL, Bender N, et al. Sexually transmitted infections and risk of epithelial ovarian cancer: results from the Nurses’ Health Studies. Br J Cancer. 2019;120(8):855-860. doi:10.1038/s41416-019-0422-9
Ingerslev K, Høgdall E, Skovrider-Ruminski W, et al. The prevalence of EBV and CMV DNA in epithelial ovarian cancer. Infect Agent Cancer. 2019;14(1). doi:10.1186/s13027-019-0223-z
zur Hausen H. Papillomaviruses in the causation of human cancers — a brief historical account. Virology. 2009;384(2):260-265. doi:10.1016/j.virol.2008.11.046
Wai KC, Strohl MP, van Zante A, Ha PK. Molecular Diagnostics in Human Papillomavirus-Related Head and Neck Squamous Cell Carcinoma. Cells. 2020;9(2):500. doi:10.3390/cells9020500
Cherif S, Amine A, Thies S, et al. Prevalence of human papillomavirus detection in ovarian cancer: a meta-analysis. European Journal of Clinical Microbiology & Infectious Diseases. 2021;40(9):1791-1802. doi:10.1007/s10096-021-04282-7
Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med. 2009;6(7). doi:10.1371/journal.pmed.1000097
Skarga E, Surcel HM, Kaaks R, Waterboer T, Fortner RT. Sexually Transmitted Infections and Risk of Epithelial Ovarian Cancer: Results From the Finnish Maternity Cohort. J Infect Dis. 2023;228(11):1621-1629. doi:10.1093/infdis/jiad171
Jonsson S, Lundin E, Elgh F, Ottander U, Idahl A. Chlamydia trachomatis and Anti-MUC1 Serology and Subsequent Risk of High-Grade Serous Ovarian Cancer: A Population-Based Case–Control Study in Northern Sweden. Transl Oncol. 2020;13(1):86-91. doi:10.1016/j.tranon.2019.09.007
Ness RB, Shen C, Bass D, et al. Chlamydia trachomatis serology in women with and without ovarian cancer. Infect Dis Obstet Gynecol. 2008;2008. doi:10.1155/2008/219672
Laban M, Ibrahim EA, Hassanin AS, et al. Chlamydia trachomatis infection in primary fallopian tube and high-grade serous ovarian cancers: A pilot study. Int J Womens Health. 2019;11:199-205. doi:10.2147/IJWH.S188938
Holster T, Urpilainen E, Paavonen J, Puistola U, Puolakkainen M. Immunological Markers of Chlamydia trachomatis Infection in Epithelial Ovarian Cancer. Anticancer Res. 2023;43(9):4037-4043. doi:10.21873/anticanres.16592
Idahl A, Le Cornet C, González Maldonado S, et al. Serologic markers of Chlamydia trachomatis and other sexually transmitted infections and subsequent ovarian cancer risk: Results from the EPIC cohort. Int J Cancer. 2020;147(8):2042-2052. doi:10.1002/ijc.32999
Yang H, Zhang J zhi, Shou C chao. Detection of mycoplasma hyorhinis infection in ovarian cancer with in situ hybridization and immunohistochemistry. Clinical Oncology and Cancer Research. 2010;7(5):294-298. doi:10.1007/s11805-010-0534-8
Bilyk OO, Pande NT, Pejovic T, Buchynska LG. THE FREQUENCY OF HUMAN PAPILLOMA VIRUS TYPES 16, 18 IN UPPER GENITAL TRACT OF WOMEN AT HIGH RISK OF DEVELOPING OVARIAN CANCER. Vol 36.; 2014.
Dadashi M, Eslami G, Faghihloo E, et al. Detection of human papilloma virus type 16 in epithelial ovarian tumors samples. Arch Clin Infect Dis. 2017;12(1). doi:10.5812/archcid.39666
Ingerslev K, Hogdall E, Skovrider-Ruminski W, et al. High-risk HPV is not associated with epithelial ovarian cancer in a Caucasian population. Infect Agent Cancer. 2016;11(1):39. doi:10.1186/s13027-016-0087-4
Kuscu E, Ozdemir BH, Erkanli S, Haberal A. HPV and p53 expression in epithelial ovarian carcinoma. Eur J Gynaecol Oncol. 2005;26(6):642-645.
Roos P, Orlando PA, Fagerstrom RM, Pepper JW. In North America, some ovarian cancers express the oncogenes of preventable human papillomavirus HPV-18. Sci Rep. 2015;5. doi:10.1038/srep08645
Shokouh MR, Safaei A, Moattari A, Sarvari J. Association of human papilloma virus and epstein-barr virus with ovarian cancer in shiraz, southwestern Iran. Iran J Pathol. 2020;15(4):292-298. doi:10.30699/ijp.2020.119681.2306
Wu QJ, Guo M, Lu ZM, Li T, Qiao HZ, Ke Y. Detection of human papillomavirus-16 in ovarian malignancy. Br J Cancer. 2003;89(4):672-675. doi:10.1038/sj.bjc.6601172
Atalay F, Taskiran C, Taner MZ, Pak I, Or M, Tuncer S. Detection of human papillomavirus DNA and genotyping in patients with epithelial ovarian carcinoma. Journal of Obstetrics and Gynaecology Research. 2007;33(6):823-828. doi:10.1111/j.1447-0756.2007.00663.x
Hassan ZK, Hafez MM, Kamel MM, Zekri ARN. Human papillomavirus genotypes and methylation of CADM1, PAX1, MAL and ADCYAP1 genes in epithelial ovarian cancer patients. Asian Pacific Journal of Cancer Prevention. 2017;18(1):169-176. doi:10.22034/APJCP.2017.18.1.169
Zhang PP, Zhou L, Cao JS, et al. Possible Epithelial Ovarian Cancer Association with HPV18 or HPV33 Infection. Asian Pac J Cancer Prev. 2016;17(6):2959-2964.
Penny SM. Ovarian Cancer: An Overview. Radiol Technol. 2020;91(6):561-575.
Polk DB, Peek RM. Helicobacter pylori: gastric cancer and beyond. Nat Rev Cancer. 2010;10(6):403-414. doi:10.1038/nrc2857
Quaglio AEV, Grillo TG, Oliveira ECS De, Stasi LC Di, Sassaki LY. Gut microbiota, inflammatory bowel disease and colorectal cancer. World J Gastroenterol. 2022;28(30):4053-4060. doi:10.3748/wjg.v28.i30.4053
Hu X, Xu X, Zeng X, et al. Gut microbiota dysbiosis promotes the development of epithelial ovarian cancer via regulating Hedgehog signaling pathway. Gut Microbes. 2023;15(1). doi:10.1080/19490976.2023.2221093
Fulbright LE, Ellermann M, Arthur JC. The microbiome and the hallmarks of cancer. PLoS Pathog. 2017;13(9):e1006480. doi:10.1371/journal.ppat.1006480
Comen EA, Bowman RL, Kleppe M. Underlying Causes and Therapeutic Targeting of the Inflammatory Tumor Microenvironment. Front Cell Dev Biol. 2018;6. doi:10.3389/fcell.2018.00056
Mahoney DE, Chalise P, Rahman F, Pierce JD. Influences of Gastrointestinal Microbiota Dysbiosis on Serum Proinflammatory Markers in Epithelial Ovarian Cancer Development and Progression. Cancers (Basel). 2022;14(12):3022. doi:10.3390/cancers14123022
Ravel J, Gajer P, Abdo Z, et al. Vaginal microbiome of reproductive-age women. Proceedings of the National Academy of Sciences. 2011;108(supplement_1):4680-4687. doi:10.1073/pnas.1002611107
Champer M, Wong A, Champer J, et al. The role of the vaginal microbiome in gynaecological cancer. BJOG. 2018;125(3):309-315. doi:10.1111/1471-0528.14631
Brotman RM, Shardell MD, Gajer P, et al. Interplay Between the Temporal Dynamics of the Vaginal Microbiota and Human Papillomavirus Detection. Journal of Infectious Diseases. 2014;210(11):1723-1733. doi:10.1093/infdis/jiu330
Gao W, Weng J, Gao Y, Chen X. Comparison of the vaginal microbiota diversity of women with and without human papillomavirus infection: a cross-sectional study. BMC Infect Dis. 2013;13(1):271. doi:10.1186/1471-2334-13-271
Walther-António MRS, Chen J, Multinu F, et al. Potential contribution of the uterine microbiome in the development of endometrial cancer. Genome Med. 2016;8(1):122. doi:10.1186/s13073-016-0368-y
Li C, Feng Y, Yang C, et al. Association between vaginal microbiota and the progression of ovarian cancer. J Med Virol. 2023;95(7). doi:10.1002/jmv.28898
Nené NR, Reisel D, Leimbach A, et al. Association between the cervicovaginal microbiome, BRCA1 mutation status, and risk of ovarian cancer: a case-control study. Lancet Oncol. 2019;20(8):1171-1182. doi:10.1016/S1470-2045(19)30340-7
Łaniewski P, Ilhan ZE, Herbst-Kralovetz MM. The microbiome and gynaecological cancer development, prevention and therapy. Nat Rev Urol. 2020;17(4):232-250. doi:10.1038/s41585-020-0286-z
Jennings LK, Krywko DM. Pelvic Inflammatory Disease.; 2024.
Chumduri C, Gurumurthy RK, Zadora PK, Mi Y, Meyer TF. Chlamydia Infection Promotes Host DNA Damage and Proliferation but Impairs the DNA Damage Response. Cell Host Microbe. 2013;13(6):746-758. doi:10.1016/j.chom.2013.05.010
Chan PJ, Seraj IM, Kalugdan TH, King A. Prevalence of Mycoplasma Conserved DNA in Malignant Ovarian Cancer Detected Using Sensitive PCR–ELISA. Gynecol Oncol. 1996;63(2):258-260. doi:10.1006/gyno.1996.0316
Shanmughapriya S, SenthilKumar G, Vinodhini K, Das BC, Vasanthi N, Natarajaseenivasan K. Viral and bacterial aetiologies of epithelial ovarian cancer. European Journal of Clinical Microbiology & Infectious Diseases. 2012;31(9):2311-2317. doi:10.1007/s10096-012-1570-5
Kurman RJ, Shih IM. The Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying Theory. American Journal of Surgical Pathology. 2010;34(3):433-443. doi:10.1097/PAS.0b013e3181cf3d79
Paavonen J, Turzanski Fortner R, Lehtinen M, Idahl A. Chlamydia trachomatis , Pelvic Inflammatory Disease, and Epithelial Ovarian Cancer. J Infect Dis. 2021;224(Supplement_2):S121-S127. doi:10.1093/infdis/jiab017
Capozzi VA, Incognito GG, Scarpelli E, et al. Exploring the Relationship between Ovarian Cancer and Genital Microbiota: A Systematic Review and Meta-Analysis. J Pers Med. 2024;14(4):351. doi:10.3390/jpm14040351
Casson N, Entenza JM, Greub G. Serological Cross-Reactivity between Different Chlamydia -Like Organisms. J Clin Microbiol. 2007;45(1):234-236. doi:10.1128/JCM.01867-06
Nour NM. Cervical cancer: a preventable death. Rev Obstet Gynecol. 2009;2(4):240-244.
Kaufman RH, Bornstein J, Gordon AN, Adam E, Kaplan AL, Adler-Storthz K. Detection of human papillomavirus DNA in advanced epithelial ovarian carcinoma. Gynecol Oncol. 1987;27(3):340-349. doi:10.1016/0090-8258(87)90256-3
Svahn MF, Faber MT, Christensen J, Norrild B, Kjaer SK. Prevalence of human papillomavirus in epithelial ovarian cancer tissue. A meta‐analysis of observational studies. Acta Obstet Gynecol Scand. 2014;93(1):6-19. doi:10.1111/aogs.12254
Chen Y, Williams V, Filippova M, Filippov V, Duerksen-Hughes P. Viral Carcinogenesis: Factors Inducing DNA Damage and Virus Integration. Cancers (Basel). 2014;6(4):2155-2186. doi:10.3390/cancers6042155
Rosa MI, Silva GD, de Azedo Simões PWT, et al. The Prevalence of Human Papillomavirus in Ovarian Cancer: A Systematic Review. International Journal of Gynecologic Cancer. 2013;23(3):437-441. doi:10.1097/IGC.0b013e318280f3e0
How to Cite
Issue
Section
License
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
How to Cite
